In the phase III OlympiA trial with 1836 early high-risk HER2- BC patients with confirmed BRCA1 or BRCA2 germline mutations, second-line olaparib treatment led to significantly longer disease-free survival (DFS) and overall survival (OS) [11,12]. Here, ERBB2 is linked to breast cancer.